The feasibility and impact of respiratory rehabilitation (RR) in patients with advanced or metastatic (EGF-R WT or mutated) non-small cell lung cancer treated with oral targeted therapy including Inhibitors of EGF-R tyrosine kinases (TKI) and ALK inhibitors. These patients will benefit, at the beginning of the chemotherapy whatever the treatment line, of a respiratory rehabilitation. The respiratory rehabilitation takes place at the patient's home with the HAD's cooperation 3 hours per week, divided into 2 or 3 sessions. There is associated educational, nutritional and psychological support for a total duration of 8 weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
25
It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
Hôpital Calmette, CHRU
Lille, France
Hôpital privé La Louvière
Lille, France
Centre hospitalier Victor Provo
Roubaix, France
Rate of patients completing the full Respiratory Rehabilitation (8 weeks) at home
Time frame: At 8 weeks
Functional Assessment of Cancer Therapy Lung standardized
measure the quality of life
Time frame: Baseline and 8 weeks
EORTC QLQ C-30 standardized version 3.0
Measure the quality of life
Time frame: Baseline and 8 weeks
Functional capacity
Exercise capacity with the six minutes walk test
Time frame: Baseline and 8 weeks
Respiratory capacity
measured by the spirometry
Time frame: Baseline and 8 weeks
Nutritional Risk Screening score
Nutritional state assessment by albumine and pre albumine dosage
Time frame: Baseline and 8 weeks
Body Mass Index
Time frame: Baseline and 8 weeks
Overall and progression-free survival
Time frame: at 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.